News

Published on 11 Feb 2024 on Simply Wall St. via Yahoo Finance

Estimating The Fair Value Of Vera Therapeutics, Inc. (NASDAQ:VERA)


Article preview image

Key Insights

Using the 2 Stage Free Cash Flow to Equity, Vera Therapeutics fair value estimate is US$46.59Vera Therapeutics' US$43.21 share price indicates it is trading at similar levels as its fair value estimate Analyst price target for VERA is US$32.11 which is 31% below our fair value estimate

Does the February share price for Vera Therapeutics, Inc. (NASDAQ:VERA) reflect what it's really worth? Today, we will estimate the stock's intrinsic value by projecting its future cash flows and then discounting them to today's value. This will be done using the Discounted Cash Flow (DCF) model. It may sound complicated, but actually it is quite simple!

NASDAQ.VERA price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
Vera Therapeutics' Atacicept Shows Sustained, Substantial Improvement In Kidney...

On Saturday, Vera Therapeutics Inc. (NASDAQ:VERA) released data from its ORIGIN Phase 2b trial of...

Benzinga · via Yahoo Finance 28 Oct 2024

Is Vera Therapeutics Inc. (VERA) the Best Performing Small-Cap Stock in 2024?

We recently compiled a list of the 10 Best Performing Small-Cap Stocks in 2024. In this article, ...

Insider Monkey · via Yahoo Finance 29 Sep 2024

Vera Therapeutics, Inc. (VERA): Among the Best Mid-Cap Healthcare Stocks To Buy...

We recently compiled a list of the 10 Best Mid-Cap Healthcare Stocks To Buy Now. In this article,...

Insider Monkey · via Yahoo Finance 19 Sep 2024

Vera Therapeutics, Inc.'s (NASDAQ:VERA) high institutional ownership speaks for itself as stock...

Key Insights Significantly high institutional ownership implies Vera Therapeutics' stock price is...

Simply Wall St. via Yahoo Finance 6 May 2024

Insider Sells at Vera Therapeutics Inc: SVP, Finance, Chief Accounting Officer Joseph Young ...

Vera Therapeutics Inc (NASDAQ:VERA), a clinical-stage biotechnology company focused on developing...

GuruFocus.com via Yahoo Finance 12 Apr 2024

Vera Therapeutics executive sells over $228k in company stock

In a recent transaction, Joseph R. Young, the Senior Vice President of Finance and Chief Accounti...

Investing.com 11 Apr 2024

Vertex's Alpine Acquisition: Unpacking Analyst Predictions on Povetacicept's Potential Impact -...

On Wednesday, Vertex Pharmaceuticals Incorporated VRTX agreed to acquire Alpine Immune Sciences I...

Benzinga 11 Apr 2024

Vertex Pharma’s takeover of Alpine Immune is a strategic fit: analysts

Alpine Immune’s lead candidate is being evaluated as a potential treatment for IgA Nephropathy, o...

Market Watch 11 Apr 2024

Vertex to Pay $4.9 Billion for Kidney Disease Drug Developer

(Bloomberg) -- Vertex Pharmaceuticals Inc. agreed to buy Alpine Immune Sciences Inc. for a total ...

Bloomberg via Yahoo Finance 11 Apr 2024

Estimating The Fair Value Of Vera Therapeutics, Inc. (NASDAQ:VERA)

Key Insights Using the 2 Stage Free Cash Flow to Equity, Vera Therapeutics fair value estimate is...

Simply Wall St. via Yahoo Finance 11 Feb 2024